Let me make sure I understand your question correctly: it is your belief or conjecture that this press release was automatically generated by a machine learning system?
— Sent from mobile, with due apologies for brevity and errors. > On Apr 1, 2021, at 3:10 PM, Brandon Svec <[email protected]> wrote: > > GPT-3? Happy April Fools Day. > > Brandon > >> On Mar 31, 2021, at 9:47 PM, Alex Balashov <[email protected]> wrote: >> >> For immediate release: >> >> GAINESVILLE, Florida (1 April 2021)--Evariste Systems, in partnership with >> Posner | Palner Pharmaceuticals, are pleased to announce the eagerly >> anticipated start of Phase III clinical trials of Kamailio DMQ module >> replication. >> >> In this stage of the investigation of the promising replication scheme, which >> was developed in record time, DMQ will be tested in a rigourous, >> double-blind, >> controlled CI/CD process for large-scale efficacy and continually monitored >> for >> safety in shorter and longer terms. >> >> The now-concluded second phase established basic safety and Phase 2b >> entailed a >> dose-finding study for the optimal number of batched `dmq_usrloc` contacts >> per >> kilogram of cloud computing resource. >> >> The main cohort of the main sequence of the Phase III trial will enroll 380 >> randomly selected, statistically representative Floridian SIP registrars and >> 5700 SIP dialogs, also in the state of Florida. When asked about the >> disparity >> in the number of registrars versus dialogs, Alex Balashov of Evariste said, >> "It >> is reflective of the small number of SIP registrars in Florida; not to be >> indelicate, but consider the median age of the population." >> >> As previously remarked upon in proceedings of the World SIP Organisation >> (WSO), >> the choice of Florida as a venue attracted some questions. We asked Fred >> Posner >> of Posner | Palner about the clinical background informing this choice of >> replication study cohort: >> >> "Florida is a good place to find eventual consistency failures; the open >> climate and reluctance to accept traditional data integrity science would >> have >> sealed the deal, but when people started to drink bleach here, I saw an >> opportunity." >> >> Evariste and Posner | Palner are aiming for a US Food & Drug Administration >> EUA >> (Emergency Use Authorisation) for DMQ replication as a prophylactic data >> redundancy and failover measure to ward off the development of moderate to >> severe viral Sonus Haemorrhagic Fever symptoms. >> >> Phase II studies have painted a promising a picture of the DMQ architecture's >> ability to reduce moderate to severe symptoms and associated 28-day mortality >> by more than 90%, albeit over a small sample size and in enterprise patients >> with known pre-existing comorbidities such as Session Border Controller and >> BroadSoft Multi-System Inflammatory Syndrome. Phase III trials seek to >> bolster >> quantums of broader efficacy, including efficacy for localised outbreaks of >> small to medium business softswitch. >> >> Of the control group, Balashov said, "They will receive a standard >> pipe-to-/dev/null placebo protocol, but with identical '200 OK' confirmation >> messages. We proudly developed this approach in early 2020 in consultation >> with >> the highest levels of the Trump presidential administration; it is called >> TENP, or 'The Emperor's New Potion.' It is a successor to that >> administration's >> previous approved placebo protocol, SHTI - Small Hands, Tremendous >> Initiatives." >> >> Despite speculative autism and packet fragmentation claims by Florida >> Governor >> Ron DeSantis, Balashov was quick to provide reassurance about side effects >> from >> DMQ in the Phase III trial. >> >> "The incidence of severe allergies to plain-text UDP was within standard >> deviation over the mean for all insecure replication, and there's support for >> other transports on the way. Anyway, we have a robust adverse effects >> reporting >> system in our issue tracker and solid surveillance. Don't let partisan >> politics >> dissuade you from allowing request lines with the KDMQ method." >> >> Other industry sources have reported that DMQ is not the only replication >> investigation undertaken by Evariste and Posner | Palner, although it is the >> only >> prophylactic suitable for the early infection development and inflammatory >> phases of a broad class of SBC-complex syndromes typically afflicting service >> providers. A recent IETF preprint by the same authors has shown high-quality >> preliminary data suggesting statistically significant improvement in >> morbidity >> outcomes from Perimeta and Nokia via a later-stage therapeutic intervention >> with a monoclonal, monorepo Github cocktail administered intravenously. >> >> >> -- >> Alex Balashov | Principal | Evariste Systems LLC >> >> Tel: +1-706-510-6800 / +1-800-250-5920 (toll-free) >> Web: http://www.evaristesys.com/, http://www.csrpswitch.com/ >> _______________________________________________ >> VoiceOps mailing list >> [email protected] >> https://puck.nether.net/mailman/listinfo/voiceops _______________________________________________ VoiceOps mailing list [email protected] https://puck.nether.net/mailman/listinfo/voiceops
